LeeESBangDLeeS. Dermatologic manifestation of Behcet's Disease. Yonsei Med J. 1997;38(6):380-389.
2.
MizushimaYInabaGMimuraY, et al.Diagnostic criteria for Behcet's Disease in 1987 and guideline for treating Behcet's Disease. Saishin Igaku. 1988;43(5):391-393.
3.
RustinMHGilkesJJRobinsonTW. Pyoderma gangrenosum associated with Behcet's Disease: treatment with thalidomide. J Am Acad Dermatol. 1990;23(5):941-944.
4.
Chams-DavatchiCShizarpourMDavatchiF, et al.Extensive pyoderma gangrenosum-like lesion in two cases of Behcet's Disease, responding only to cyclosporine. Adv Exp Med Biol. 2003;528:337-338.
5.
DüzgünNAtesAAydintugOT, et al.Characteristics of vascular involvement in Behcet's Disease. Scand J Rheumatol. 2006;35(1):65-68.
6.
PlotkinGRPatelBRShahVN. Behçet's Syndrome complicated by cutaneous leukocytoclastic vasculitis. Response to prednisone and chlorambucil. Arch Intern Med. 1985;145(10):1913-1915.
7.
OzoranKDüzgünNGurlerA, et al.Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's Disease. Scand J Rheumatol. 1995;24(6):376-382.
8.
KosarAOzturkMHaznedarogluIC, et al.Hemostatic parameters in Behcet's Disease: a reappraisal. Rheumatol Int. 2002;22(1):9-15.
9.
HizliNSahinGSahinF, et al.Plasma prostacyclin levels in Behcet's Disease. Lancet. 1985;1(8443):1454.
10.
UralAU. Increased plasma endothelin-1 levels in active Behcet's Disease. Clin Rheumatol. 1997;16(6):59-61.
